Display options
Cite
Goldman VE, Naguib MN, Vidmar AP. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search. J Clin Med. 2021;10(19)doi: 10.3390/jcm10194540.
Goldman, V. E., Naguib, M. N., & Vidmar, A. P. (2021). Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search. Journal of clinical medicine, 10(19), . https://doi.org/10.3390/jcm10194540
Goldman, Victoria E, et al. "Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search." Journal of clinical medicine vol. 10,19 (2021). doi: https://doi.org/10.3390/jcm10194540
Goldman VE, Naguib MN, Vidmar AP. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search. J Clin Med. 2021 Sep 30;10(19). doi: 10.3390/jcm10194540. PMID: 34640558; PMCID: PMC8509766.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2021 Sep 30;10(19). doi: 10.3390/jcm10194540.

Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.

Journal of clinical medicine

Victoria E Goldman, Monica N Naguib, Alaina P Vidmar

Affiliations

  1. Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
  2. Center for Endocrinology, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
  3. Department of Pediatrics, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.

PMID: 34640558 PMCID: PMC8509766 DOI: 10.3390/jcm10194540

Abstract

(1) Background: children with Prader-Willi syndrome (PWS) have high obesity rates due to hyperphagia and decreased metabolic rates. Although anti-obesity medications (AOMs) are prescribed to this population, there are no consensus guidelines on acceptability, safety, and efficacy. We present literature review and case series on AOMs in youth with PWS. (2) Methods: we performed PubMed review from January 2000 to April 2021 utilizing keywords: "Prader-Willi syndrome" or "PWS" and "medication" including: topiramate, metformin, phentermine, liraglutide, orlistat, oxytocin, semaglutide, naltrexone-bupropion. For our case series, patients were identified through retrospective chart reviews from a multi-disciplinary PWS clinic. Eligibility criteria: age ≤ 18 years, genetically confirmed PWS, AOM use for at least 16 weeks, and recent anthropometric data. (3) Results: a literature search yielded 14 articles (3 topiramate, 1 metformin, 4 liraglutide, 5 oxytocin, 1 naltrexone-bupropion). All studies reported improved hyperphagia with variable BMI effects. Ten adolescents met case series eligibility (mean age 13.2 ± 2.6 years, 40% female; AOMs: 6 metformin, 5 topiramate, 2 semaglutide, 3 liraglutide). After AOM course, 60% had decreased or stable BMI z-score. No significant side effects. (4) Conclusions: results suggest AOMs may be useful for weight management in youth with PWS. Additional studies are required to validate findings and support AOM treatment guidelines.

Keywords: Prader-Willi syndrome; anti-obesity medication; liraglutide; metformin; naltrexone-bupropion; oxytocin; semaglutide; topiramate

References

  1. JAMA. 2017 Jun 20;317(23):2427-2444 - PubMed
  2. Clin Endocrinol (Oxf). 2016 Dec;85(6):979-987 - PubMed
  3. Curr Obes Rep. 2019 Jun;8(2):156-164 - PubMed
  4. Expert Opin Drug Saf. 2018 Apr;17(4):379-385 - PubMed
  5. PLoS One. 2019 Sep 23;14(9):e0221615 - PubMed
  6. J Child Adolesc Psychopharmacol. 2016 May;26(4):403-4 - PubMed
  7. J Pediatr Endocrinol Metab. 2014 Jan;27(1-2):23-9 - PubMed
  8. Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):56-62 - PubMed
  9. Endocr J. 2012;59(10):889-94 - PubMed
  10. Am J Med Genet A. 2017 May;173(5):1243-1250 - PubMed
  11. Diabet Med. 2011 Jun;28(6):755-6 - PubMed
  12. Pediatr Neurol. 2003 Feb;28(2):130-3 - PubMed
  13. Diabetes Obes Metab. 2017 Dec;19(12):1751-1761 - PubMed
  14. Mol Genet Metab. 2018 Apr;123(4):511-517 - PubMed
  15. Clin Pediatr Endocrinol. 2020;29(2):81-84 - PubMed
  16. Ann Pharmacother. 2013 Mar;47(3):340-9 - PubMed
  17. J Korean Med Sci. 2021 Jan 18;36(3):e21 - PubMed
  18. Med Clin North Am. 2018 Jan;102(1):135-148 - PubMed
  19. JAMA. 2015 Mar 24-31;313(12):1213-4 - PubMed
  20. Nat Rev Endocrinol. 2017 Dec;13(12):700-709 - PubMed
  21. Front Endocrinol (Lausanne). 2019 Apr 12;10:155 - PubMed
  22. Endocr Rev. 2020 Apr 1;41(2): - PubMed
  23. Eur J Endocrinol. 2020 Nov;183(5):R149-R166 - PubMed
  24. Pediatr Diabetes. 2017 Feb;18(1):10-16 - PubMed
  25. J Endocrinol Invest. 2021 Oct;44(10):2057-2070 - PubMed
  26. Obes Rev. 2020 May;21(5):e12992 - PubMed
  27. Obes Rev. 2011 May;12(5):e338-47 - PubMed
  28. Curr Obes Rep. 2020 Dec;9(4):442-450 - PubMed
  29. Am J Ment Retard. 2004 Jul;109(4):301-9 - PubMed
  30. Am J Med Genet A. 2014 Sep;164A(9):2232-9 - PubMed
  31. Lancet. 2008 Nov 29;372(9653):1906-1913 - PubMed
  32. J Pediatr Endocrinol Metab. 2020 Jul 28;33(7):951-955 - PubMed
  33. Nature. 2012 Aug 9;488(7410):172-7 - PubMed
  34. Obes Rev. 2019 Jun;20(6):805-815 - PubMed
  35. Drugs. 2018 Dec;78(18):1887-1901 - PubMed
  36. Mol Ther Methods Clin Dev. 2019 Mar 14;13:344-358 - PubMed
  37. Ann Pediatr Endocrinol Metab. 2020 Mar;25(1):52-56 - PubMed
  38. Genet Med. 2012 Jan;14(1):10-26 - PubMed
  39. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):323-9 - PubMed
  40. Int J Neuropsychopharmacol. 2002 Jun;5(2):141-5 - PubMed
  41. Diabetes Metab Syndr Obes. 2018 Oct 04;11:579-593 - PubMed
  42. Transl Psychiatry. 2019 Nov 4;9(1):274 - PubMed
  43. Curr Obes Rep. 2018 Jun;7(2):147-161 - PubMed
  44. PLoS One. 2018 Jan 10;13(1):e0190849 - PubMed
  45. Clin Endocrinol (Oxf). 2021 May;94(5):774-785 - PubMed
  46. Diabetes Care. 2014 Apr;37(4):e76-7 - PubMed
  47. Br J Pharmacol. 2016 Sep;173(17):2614-21 - PubMed
  48. J Psychiatr Res. 2021 May;137:643-651 - PubMed
  49. Ment Health Clin. 2018 Mar 23;7(1):7-9 - PubMed

Publication Types

Grant support